JP2024529975A5 - - Google Patents
Info
- Publication number
- JP2024529975A5 JP2024529975A5 JP2024505286A JP2024505286A JP2024529975A5 JP 2024529975 A5 JP2024529975 A5 JP 2024529975A5 JP 2024505286 A JP2024505286 A JP 2024505286A JP 2024505286 A JP2024505286 A JP 2024505286A JP 2024529975 A5 JP2024529975 A5 JP 2024529975A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sequence
- rna molecule
- composition
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227972P | 2021-07-30 | 2021-07-30 | |
| US63/227,972 | 2021-07-30 | ||
| PCT/US2022/074337 WO2023010128A2 (en) | 2021-07-30 | 2022-07-29 | Rna vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024529975A JP2024529975A (ja) | 2024-08-14 |
| JP2024529975A5 true JP2024529975A5 (https=) | 2025-08-05 |
Family
ID=85088269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505286A Pending JP2024529975A (ja) | 2021-07-30 | 2022-07-29 | Ｒｎａワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230219996A1 (https=) |
| EP (1) | EP4376883A4 (https=) |
| JP (1) | JP2024529975A (https=) |
| KR (1) | KR20240050353A (https=) |
| CN (1) | CN118043068A (https=) |
| AR (1) | AR126625A1 (https=) |
| AU (1) | AU2022319940A1 (https=) |
| BR (1) | BR112024001911A2 (https=) |
| CA (1) | CA3226806A1 (https=) |
| CR (1) | CR20240095A (https=) |
| IL (1) | IL310107A (https=) |
| MX (1) | MX2024001464A (https=) |
| TW (1) | TW202313967A (https=) |
| WO (1) | WO2023010128A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021236068A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| EP4196128A4 (en) | 2020-08-14 | 2024-06-12 | Arcturus Therapeutics, Inc. | METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES |
| WO2024211625A1 (en) * | 2023-04-07 | 2024-10-10 | Arcturus Therapeutics, Inc. | Hbv gene editing |
| TW202539706A (zh) * | 2023-11-14 | 2025-10-16 | 大陸商上海瑞宏迪醫藥有限公司 | 一種脂質奈米粒的製備方法和應用 |
| WO2025161942A1 (zh) * | 2024-02-02 | 2025-08-07 | 仁景(苏州)生物科技有限公司 | 用于递送的脂质化合物和脂质纳米颗粒 |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| CN121021427A (zh) * | 2024-07-30 | 2025-11-28 | 广州市恒诺康医药科技有限公司 | 可离子化脂质及其用途 |
| JP7657411B1 (ja) * | 2025-01-23 | 2025-04-07 | 医療法人すぎやま内科 | 乳がん細胞の増殖抑制剤及び乳がん治療剤 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2922554T3 (pl) * | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| AU2016354102B2 (en) * | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| CA3045650A1 (en) * | 2016-12-05 | 2018-06-14 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| MA51523A (fr) * | 2018-01-05 | 2020-11-11 | Modernatx Inc | Polynucléotides codant pour des anticorps anti-virus du chikungunya |
| WO2020076775A1 (en) * | 2018-10-08 | 2020-04-16 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| US11406699B2 (en) * | 2019-03-22 | 2022-08-09 | George Mason University | Alphavirus and compositions, methods, and kits related thereto |
| WO2020209929A1 (en) * | 2019-04-09 | 2020-10-15 | Massachusetts Institute Of Technology | Mutant subgenomic promoter library and uses thereof |
| EP3986452A1 (en) * | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| AU2020298267A1 (en) * | 2019-06-20 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Self-replicating RNA molecules for hepatitis B virus (HBV) vaccines and uses thereof |
| CR20220220A (es) * | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| US12194089B2 (en) * | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| AU2021236068A1 (en) * | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| EP4157344A2 (en) * | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
-
2022
- 2022-07-29 TW TW111128541A patent/TW202313967A/zh unknown
- 2022-07-29 CR CR20240095A patent/CR20240095A/es unknown
- 2022-07-29 CN CN202280058353.XA patent/CN118043068A/zh active Pending
- 2022-07-29 EP EP22850552.5A patent/EP4376883A4/en active Pending
- 2022-07-29 WO PCT/US2022/074337 patent/WO2023010128A2/en not_active Ceased
- 2022-07-29 BR BR112024001911A patent/BR112024001911A2/pt unknown
- 2022-07-29 US US17/816,243 patent/US20230219996A1/en active Pending
- 2022-07-29 AR ARP220102043A patent/AR126625A1/es unknown
- 2022-07-29 IL IL310107A patent/IL310107A/en unknown
- 2022-07-29 MX MX2024001464A patent/MX2024001464A/es unknown
- 2022-07-29 KR KR1020247007128A patent/KR20240050353A/ko active Pending
- 2022-07-29 JP JP2024505286A patent/JP2024529975A/ja active Pending
- 2022-07-29 AU AU2022319940A patent/AU2022319940A1/en active Pending
- 2022-07-29 CA CA3226806A patent/CA3226806A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024529975A5 (https=) | ||
| JP2023517644A5 (https=) | ||
| US11744887B2 (en) | Coronavirus vaccine compositions and methods | |
| US12350330B2 (en) | RSV RNA molecules and compositions for vaccination | |
| Fang et al. | Advances in COVID-19 mRNA vaccine development | |
| US20240398940A1 (en) | Novel lipid nanoparticles for delivery of nucleic acids | |
| ES2968649T3 (es) | Nanopartículas lipídicas para la administración de ARNm en los pulmones | |
| US20230219996A1 (en) | Rna vaccines | |
| BR112021010611A2 (pt) | Composições e métodos de vacina de reforço (prime boost) heterólogo | |
| JP2024534900A (ja) | ホスファチジルセリンを含む核酸を送達するための新規な脂質ナノ粒子 | |
| US20220016237A1 (en) | Rna replicon vaccines against hbv | |
| US11559561B2 (en) | Composition and methods for treatment of primary ciliary dyskinesia | |
| CA3215112A1 (en) | Compositions and methods for delivery of rna | |
| US20220054611A1 (en) | Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer | |
| JP2026509258A (ja) | 核酸送達のための新規な脂質ナノ粒子製剤 | |
| WO2024152996A1 (zh) | 自复制信使核糖核酸疫苗 | |
| US20240301007A1 (en) | Methods and compositions for quadrivalent influenza vaccine | |
| CN117940118A (zh) | 用于核酸递送的新型脂质纳米颗粒 | |
| WO2026029847A1 (en) | Methods and compositions for pandemic influenza vaccine | |
| HK40110708A (zh) | Rna疫苗 | |
| CN117440824A (zh) | 抗SARS-CoV-2变体的RNA疫苗 | |
| KR20260048662A (ko) | Sars-cov-2 rna 백신 및 이의 용도 | |
| CN118119404A (zh) | 免疫原性lnp组合物及其方法 | |
| HK40091626A (zh) | 针对hbv的rna复制子疫苗 |